{
  "page_id": 1,
  "metadata": {
    "file_name": "doc_0609.png",
    "image_width": 754,
    "image_height": 1000
  },
  "lines": [
    {
      "text": "Rov. 1: 1995",
      "bbox": [
        64,
        10,
        150,
        33
      ],
      "confidence": 0.7754094004631042
    },
    {
      "text": "L:41FM",
      "bbox": [
        166,
        17,
        212,
        32
      ],
      "confidence": 0.7421007752418518
    },
    {
      "text": "No. 0332",
      "bbox": [
        566,
        12,
        624,
        30
      ],
      "confidence": 0.9334418773651123
    },
    {
      "text": "P. 8/6",
      "bbox": [
        619,
        10,
        690,
        33
      ],
      "confidence": 0.8417086005210876
    },
    {
      "text": "Biography of Jonathan K.C. Knowles",
      "bbox": [
        253,
        105,
        539,
        132
      ],
      "confidence": 0.9938444495201111
    },
    {
      "text": "Director, Glaxo Institute for Molecular Biology, Geneva, Switzeriand",
      "bbox": [
        215,
        126,
        579,
        150
      ],
      "confidence": 0.9741040468215942
    },
    {
      "text": "Glaxo Welicome Research Director for Europe",
      "bbox": [
        271,
        145,
        521,
        166
      ],
      "confidence": 0.9941188097000122
    },
    {
      "text": "Jonathan Knowies was appointed director of the Glaxo Institute for Molecular Biclogy in Geneva in",
      "bbox": [
        118,
        261,
        675,
        283
      ],
      "confidence": 0.9822057485580444
    },
    {
      "text": "1989. Over the last five years under his leadership, the 180-strong Institute has developed significant",
      "bbox": [
        119,
        279,
        675,
        299
      ],
      "confidence": 0.988372266292572
    },
    {
      "text": "expertise in the diverse technologies essential for the discovery and definition of important novel drug",
      "bbox": [
        118,
        295,
        675,
        318
      ],
      "confidence": 0.9761495590209961
    },
    {
      "text": "targets. It has made a significant contribution to Glaxo's intemational drug discovery effort, and",
      "bbox": [
        117,
        312,
        675,
        334
      ],
      "confidence": 0.9828043580055237
    },
    {
      "text": "developed a gcod scientific reputation in a number of key areas of modern biology. Jonathan Knowles",
      "bbox": [
        118,
        329,
        675,
        350
      ],
      "confidence": 0.9639902710914612
    },
    {
      "text": "is responsible for the international co-ordination of the Glaxo Human Genetics Initiative. In 1995, in",
      "bbox": [
        117,
        345,
        675,
        366
      ],
      "confidence": 0.975426971912384
    },
    {
      "text": "addition to his function as Director of the Glaxo Institute at Geneva, he was appointed as Research",
      "bbox": [
        118,
        364,
        675,
        382
      ],
      "confidence": 0.9885338544845581
    },
    {
      "text": "Director for Glaxo Welicome Europe. He is also a member of the Global Research and Development",
      "bbox": [
        119,
        381,
        675,
        399
      ],
      "confidence": 0.9953741431236267
    },
    {
      "text": "Executive Committee, which oversees all Glaxo Weilcome Research and Development activities",
      "bbox": [
        120,
        398,
        675,
        415
      ],
      "confidence": 0.9803768396377563
    },
    {
      "text": "world-wide.",
      "bbox": [
        119,
        416,
        186,
        433
      ],
      "confidence": 0.9996165633201599
    },
    {
      "text": "Before joining Glaxo, Jonathan Knowies was head of mclecular biology at the Technical Research",
      "bbox": [
        120,
        448,
        675,
        467
      ],
      "confidence": 0.9834054112434387
    },
    {
      "text": "Centre of Finland for 10 years. He directed a multidisciplinary group exploiting molecular biology for",
      "bbox": [
        118,
        464,
        677,
        486
      ],
      "confidence": 0.9756971597671509
    },
    {
      "text": "the development of new proteins and industrial organisms for biotech applications in the production of",
      "bbox": [
        118,
        481,
        679,
        502
      ],
      "confidence": 0.9778568744659424
    },
    {
      "text": "food, paper, diagnostics and pharmaceuticals. He has a broad interest in biciogy and in particular its",
      "bbox": [
        120,
        500,
        677,
        517
      ],
      "confidence": 0.9795511960983276
    },
    {
      "text": "applications which he has pursued in research organisations in the UK, France, Germany, the US,",
      "bbox": [
        119,
        515,
        678,
        536
      ],
      "confidence": 0.9894524216651917
    },
    {
      "text": "Finland, Japan, and Switzerland.",
      "bbox": [
        122,
        536,
        296,
        550
      ],
      "confidence": 0.9983518123626709
    },
    {
      "text": "Education: BSc, University of East Anglia and PhD, University of Edinburgh, Scotland.",
      "bbox": [
        120,
        603,
        597,
        620
      ],
      "confidence": 0.9891793727874756
    },
    {
      "text": "Family:",
      "bbox": [
        117,
        638,
        170,
        655
      ],
      "confidence": 0.9554076790809631
    },
    {
      "text": "He Iives with his wife Kirsti and three children in Geneva.",
      "bbox": [
        176,
        639,
        497,
        653
      ],
      "confidence": 0.9769142866134644
    },
    {
      "text": "Hobbies: Sailing, Skiing, Music and Flying.",
      "bbox": [
        116,
        671,
        365,
        691
      ],
      "confidence": 0.9698633551597595
    },
    {
      "text": "September 1995",
      "bbox": [
        110,
        840,
        207,
        865
      ],
      "confidence": 0.9647606611251831
    },
    {
      "text": "2048225724",
      "bbox": [
        736,
        864,
        753,
        961
      ],
      "confidence": 0.9997539520263672
    }
  ],
  "full_text": "Rov. 1: 1995\nL:41FM\nNo. 0332\nP. 8/6\nBiography of Jonathan K.C. Knowles\nDirector, Glaxo Institute for Molecular Biology, Geneva, Switzeriand\nGlaxo Welicome Research Director for Europe\nJonathan Knowies was appointed director of the Glaxo Institute for Molecular Biclogy in Geneva in\n1989. Over the last five years under his leadership, the 180-strong Institute has developed significant\nexpertise in the diverse technologies essential for the discovery and definition of important novel drug\ntargets. It has made a significant contribution to Glaxo's intemational drug discovery effort, and\ndeveloped a gcod scientific reputation in a number of key areas of modern biology. Jonathan Knowles\nis responsible for the international co-ordination of the Glaxo Human Genetics Initiative. In 1995, in\naddition to his function as Director of the Glaxo Institute at Geneva, he was appointed as Research\nDirector for Glaxo Welicome Europe. He is also a member of the Global Research and Development\nExecutive Committee, which oversees all Glaxo Weilcome Research and Development activities\nworld-wide.\nBefore joining Glaxo, Jonathan Knowies was head of mclecular biology at the Technical Research\nCentre of Finland for 10 years. He directed a multidisciplinary group exploiting molecular biology for\nthe development of new proteins and industrial organisms for biotech applications in the production of\nfood, paper, diagnostics and pharmaceuticals. He has a broad interest in biciogy and in particular its\napplications which he has pursued in research organisations in the UK, France, Germany, the US,\nFinland, Japan, and Switzerland.\nEducation: BSc, University of East Anglia and PhD, University of Edinburgh, Scotland.\nFamily:\nHe Iives with his wife Kirsti and three children in Geneva.\nHobbies: Sailing, Skiing, Music and Flying.\nSeptember 1995\n2048225724"
}